NASDAQInformation TechnologyRental & Leasing ServicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for LIME yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Disciplined capital allocation with credit facility and buybacks | The company aims for disciplined capital allocation with a new $200 million credit facility. | Intact | fails to maintain the $200 million credit facility | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · alphavantage
$1.43 → $1.27 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
LIME is a growth-sensitive Tech business, but the available evidence does not establish it as a durable compounder or a turnaround. The thesis is insufficiently tested because recent financial history is limited, while the risk label has risen from elevated to high.
The snapshot does not provide a valuation measure or clear evidence of what market expectations already assume, so valuation cannot be described as cheap, fair, or expensive versus peers. The priced-in evidence only indicates low fragility, with no fragility gates triggered.
Near term, management has reported revenue of $304.2 million and operating income of $12.8 million for 2026-Q2, repaid a $115 million term loan using IPO proceeds, and introduced a credit facility and buyback program. These are early signals, and the trajectory for growth, profitability, and capital allocation remains to be assessed in later quarters.
Over the next few quarters, the thesis depends on whether LIME can show sustained revenue growth and profitability while managing its financial obligations. Fed rate cuts or stabilization among major Tech companies could help the sector backdrop, while GDP growth slowing below 2% could weigh more heavily on growth-sensitive Tech businesses.
For the 1-3 year view, LIME has some positive balance-sheet and operating evidence, but limited history and high risk leave the thesis uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in NEUTRON HOLDINGS INC's published investment case. The stated target is repay $115 million senior secured term loan facility. |
| Recovered |
| fails to repay the $115 million term loan |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth and profitability improvement | A primary condition in NEUTRON HOLDINGS INC's published investment case. The stated target is >=15% YoY. | Intact | falls below 15% YoY revenue growth next year | Required source inputs unavailable Cannot calculate Revenue growth from the available matching source inputs. Missing inputs are not treated as zero. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$1.23B → $1.23B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-19 | $1.43 | $1,230,072,730 | 3 / 8 |
| 2026-10-20 | $1.43 | $1,230,072,730 | 3 / 8 |
| 2026-10-21 | $1.43 | $1,230,072,730 | 3 / 8 |
| 2026-10-22 | $1.43 | $1,230,072,730 | 3 / 8 |
| 2026-10-23 | $1.43 | $1,230,072,730 | 3 / 8 |
| 2026-10-24 | $1.43 | $1,230,072,730 | 3 / 8 |
| 2026-10-25 | $1.43 | $1,230,072,730 | 3 / 8 |
| 2026-10-26 | $1.43 | $1,230,072,730 | 3 / 8 |
| 2026-10-27 | $1.27 | $1,234,672,730 | 2 / 8 |
| 2026-10-28 | $1.27 | $1,234,672,730 | 2 / 8 |
| 2026-10-29 | $1.27 | $1,234,672,730 | 2 / 8 |
| 2026-10-30 | $1.27 | $1,234,672,730 | 2 / 8 |
| 2026-10-31 | $1.27 | $1,234,672,730 | 2 / 8 |
| 2026-11-01 | $1.27 | $1,234,672,730 | 2 / 8 |
| 2026-11-02 | $1.27 | $1,234,672,730 | 2 / 8 |
| 2026-11-03 | $1.27 | $1,234,672,730 | 2 / 8 |
| 2026-11-04 | $1.27 | $1,234,672,730 | 2 / 8 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 5 recorded
0 raises · 3 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.